PRIMARY OBJECTIVE: Whilst there is data to support the use of Melatonin in treating disorders of the sleep-wake cycle, so far there is little published evidence on the efficacy of Melatonin in treating the prevalent condition of post-TBI sleep disturbance. RESEARCH DESIGN: The present work used a randomized double-blind controlled cross-over trial to compare Melatonin (5 mg) and Amitriptyline (25 mg) in a small sample of TBI patients presenting with chronic sleep disturbance. MAIN OUTCOME AND RESULTS: No differences in sleep latency, duration, quality or daytime alertness were found for either drug compared to baseline using significance testing. However, effect sizes revealed some encouraging changes. Patients on Melatonin reported improved daytime alertness compared to baseline. On Amitriptyline, patients reported increased sleep duration compared to baseline. CONCLUSIONS: The study provides preliminary evidence for the value of Melatonin and Amitriptyline in treating sleep disorder post-TBI. There were no adverse drug effects. Suggestions are made for ongoing investigation for the treatment of this prevalent condition. Copyright 2004 Taylor and Francis Ltd
RCT Entities:
PRIMARY OBJECTIVE: Whilst there is data to support the use of Melatonin in treating disorders of the sleep-wake cycle, so far there is little published evidence on the efficacy of Melatonin in treating the prevalent condition of post-TBIsleep disturbance. RESEARCH DESIGN: The present work used a randomized double-blind controlled cross-over trial to compare Melatonin (5 mg) and Amitriptyline (25 mg) in a small sample of TBIpatients presenting with chronic sleep disturbance. MAIN OUTCOME AND RESULTS: No differences in sleep latency, duration, quality or daytime alertness were found for either drug compared to baseline using significance testing. However, effect sizes revealed some encouraging changes. Patients on Melatonin reported improved daytime alertness compared to baseline. On Amitriptyline, patients reported increased sleep duration compared to baseline. CONCLUSIONS: The study provides preliminary evidence for the value of Melatonin and Amitriptyline in treating sleep disorder post-TBI. There were no adverse drug effects. Suggestions are made for ongoing investigation for the treatment of this prevalent condition. Copyright 2004 Taylor and Francis Ltd
Authors: Angela Lumba-Brown; Keith Owen Yeates; Kelly Sarmiento; Matthew J Breiding; Tamara M Haegerich; Gerard A Gioia; Michael Turner; Edward C Benzel; Stacy J Suskauer; Christopher C Giza; Madeline Joseph; Catherine Broomand; Barbara Weissman; Wayne Gordon; David W Wright; Rosemarie Scolaro Moser; Karen McAvoy; Linda Ewing-Cobbs; Ann-Christine Duhaime; Margot Putukian; Barbara Holshouser; David Paulk; Shari L Wade; Stanley A Herring; Mark Halstead; Heather T Keenan; Meeryo Choe; Cindy W Christian; Kevin Guskiewicz; P B Raksin; Andrew Gregory; Anne Mucha; H Gerry Taylor; James M Callahan; John DeWitt; Michael W Collins; Michael W Kirkwood; John Ragheb; Richard G Ellenbogen; Theodore J Spinks; Theodore G Ganiats; Linda J Sabelhaus; Katrina Altenhofen; Rosanne Hoffman; Tom Getchius; Gary Gronseth; Zoe Donnell; Robert E O'Connor; Shelly D Timmons Journal: JAMA Pediatr Date: 2018-11-05 Impact factor: 16.193
Authors: Emerson M Wickwire; David M Schnyer; Anne Germain; Scott G Williams; Christopher J Lettieri; Ashlee B McKeon; Steven M Scharf; Ryan Stocker; Jennifer Albrecht; Neeraj Badjatia; Amy J Markowitz; Geoffrey T Manley Journal: J Neurotrauma Date: 2018-08-24 Impact factor: 5.269
Authors: Marisa B Osorio; Brad G Kurowski; Dean Beebe; H Gerry Taylor; Tanya M Brown; Michael W Kirkwood; Shari L Wade Journal: PM R Date: 2013-01-29 Impact factor: 2.298
Authors: Emerson M Wickwire; Scott G Williams; Thomas Roth; Vincent F Capaldi; Michael Jaffe; Margaret Moline; Gholam K Motamedi; Gregory W Morgan; Vincent Mysliwiec; Anne Germain; Renee M Pazdan; Reuven Ferziger; Thomas J Balkin; Margaret E MacDonald; Thomas A Macek; Michael R Yochelson; Steven M Scharf; Christopher J Lettieri Journal: Neurotherapeutics Date: 2016-04 Impact factor: 7.620